Kiniksa Pharmaceuticals International, plc

For the period ended Jun 30, 2025. Filed Jul 29, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 29, 2025

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 5. Other Information

Trading Arrangements

The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as such terms are defined under Item 408 of Regulation S-K) adopted, amended or terminated by our directors and officers during the three months ended June 30, 2025:

E
· · · · Trading Arrangement · ·
Name	Title	Action	Effective Date	Rule 10b5-1	Non Rule 10b5-1	Scheduled Expiration Date of Trading Plan(1)	Maximum Shares Subject to Trading Plan
Sanj K. Patel	CEO and Chairman of the Board	Adoption	May 7, 2025	X		October 19, 2026	355,590(2)
Michael R. Megna	SVP, Finance and Chief Accounting Officer	Adoption	May 24, 2025	X		September 15, 2026	36,145(3)

(1)	A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement or as otherwise provided in the trading arrangement.

(2)	This figure includes a number of securities covered by a currently active plan and, therefore, may be less at the time that this plan goes into effect.

(3)	Includes Class A ordinary shares to be received upon the vesting of outstanding RSUs. The final amount of shares available for sale will be lower due to our net vesting policy for employee RSUs.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.